Warning (2) : Undefined array key "profile" [in /home/marketcap/public_html/src/Controller/HomesController.php, line 242]
Warning (2) : Trying to access array offset on value of type null [in /home/marketcap/public_html/src/Controller/HomesController.php, line 242]
Warning (2) : Undefined array key "profile" [in /home/marketcap/public_html/src/Controller/HomesController.php, line 243]
Warning (2) : Trying to access array offset on value of type null [in /home/marketcap/public_html/src/Controller/HomesController.php, line 243]
Warning (512) : Unable to emit headers. Headers sent in file=/home/marketcap/public_html/vendor/cakephp/cakephp/src/Error/Renderer/HtmlErrorRenderer.php line=36 [in /home/marketcap/public_html/vendor/cakephp/cakephp/src/Http/ResponseEmitter.php, line 71]
Warning (2) : Cannot modify header information - headers already sent by (output started at /home/marketcap/public_html/vendor/cakephp/cakephp/src/Error/Renderer/HtmlErrorRenderer.php:36) [in /home/marketcap/public_html/vendor/cakephp/cakephp/src/Http/ResponseEmitter.php, line 168]
Warning (2) : Cannot modify header information - headers already sent by (output started at /home/marketcap/public_html/vendor/cakephp/cakephp/src/Error/Renderer/HtmlErrorRenderer.php:36) [in /home/marketcap/public_html/vendor/cakephp/cakephp/src/Http/ResponseEmitter.php, line 197]
Warning (2) : Cannot modify header information - headers already sent by (output started at /home/marketcap/public_html/vendor/cakephp/cakephp/src/Error/Renderer/HtmlErrorRenderer.php:36) [in /home/marketcap/public_html/vendor/cakephp/cakephp/src/Http/ResponseEmitter.php, line 236]
MediciNova, Inc. - Market capitalization
MediciNova, Inc.
MNOV

$97.11 M
Marketcap
$1.98
Share price
Country
N/A
Change (1 day)
N/A
Year High
N/A
Year Low
Categories

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction. Its product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic diseases, including nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. The company has collaboration agreements with Kissei Pharmaceutical Co., Ltd.; Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals Ltd.; and Meiji Seika Kaisha Ltd. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.

marketcap